The Efficiency and Toxicity OfAnlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phase II Study

被引：1
作者：
Chen, Xi [1 ]
Wei, Xinyu [1 ]
Yao, Peizhuo [1 ]
Liu, Yanbin [1 ]
Guan, Haitao [2 ]
Kang, Huafeng [2 ]
Liu, Di [2 ]
Diao, Yan [2 ]
Ma, Xiaobin [2 ]
Min, Weili [2 ]
Shan, Changyou [2 ]
Zhao, Yang [2 ]
Zhao, Fang [2 ]
Chen, Yuanyuan [3 ]
Xiao, Dong [4 ]
She, Qing [3 ]
Liu, Youhuai [3 ]
Zhang, Yinbin [2 ]
Zhang, Shuqun [2 ]
机构：
[1] Xi An Jiao Tong Univ, Xian, Shaanxi, Peoples R China
[2] Xi An Jiao Tong Univ, Affiliated Hosp 2, 157,West 5th Rd, Xian 710004, Shaanxi, Peoples R China
[3] Baoji Cent Hosp Shaanxi Prov, Baoji, Shaanxi, Peoples R China
[4] 3201 Hosp Hanzhong City, Hanzhong, Shaanxi, Peoples R China
来源：
CLINICAL BREAST CANCER | 2024年 / 24卷 / 04期
关键词：
1ST-LINE TREATMENT; BEVACIZUMAB; PACLITAXEL; INHIBITOR; EFFICACY; CHEMOTHERAPY; KINASE; SAFETY; TRIAL;
D O I：
10.1016/j.clbc.2024.01.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：195 / 202
页数：8
相关论文
共 34 条
  • [21] pubmed, RECIST 1.1-standardisation and disease-specific adaptations: perspectives from the RECIST Working Group
  • [22] Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer
    Ribatti, Domenico
    Nico, Beatrice
    Ruggieri, Simona
    Tamma, Roberto
    Simone, Giovanni
    Mangia, Anita
    [J]. TRANSLATIONAL ONCOLOGY, 2016, 9 (05): : 453 - 457
  • [23] Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial
    Robert, Nicholas J.
    Saleh, Mansoor N.
    Paul, Devchand
    Generali, Daniele
    Gressot, Laurent
    Copur, Mehmet S.
    Brufsky, Adam M.
    Minton, Susan E.
    Giguere, Jeffrey K.
    Smith, John W., II
    Richards, Paul D.
    Gernhardt, Diana
    Huang, Xin
    Liau, Katherine F.
    Kern, Kenneth A.
    Davis, John
    [J]. CLINICAL BREAST CANCER, 2011, 11 (02) : 82 - 92
  • [24] RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer
    Robert, Nicholas J.
    Dieras, Veronique
    Glaspy, John
    Brufsky, Adam M.
    Bondarenko, Igor
    Lipatov, Oleg N.
    Perez, Edith A.
    Yardley, Denise A.
    Chan, Stephen Y. T.
    Zhou, Xian
    Phan, See-Chun
    O'Shaughnessy, Joyce
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (10) : 1252 - 1260
  • [25] The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab)
    Sasich, Larry D.
    Sukkari, Sana Rikabi
    [J]. SAUDI PHARMACEUTICAL JOURNAL, 2012, 20 (04) : 381 - 385
  • [26] Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial
    Schneider, Bryan P.
    Gray, Robert J.
    Radovich, Milan
    Shen, Fei
    Vance, Gail
    Li, Lang
    Jiang, Guanglong
    Miller, Kathy D.
    Gralow, Julie R.
    Dickler, Maura N.
    Cobleigh, Melody A.
    Perez, Edith A.
    Shenkier, Tamara N.
    Nielsen, Kirsten Vang
    Muller, Sven
    Thor, Ann
    Sledge, George W., Jr.
    Sparano, Joseph A.
    Davidson, Nancy E.
    Badve, Sunil S.
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (05) : 1281 - 1289
  • [27] Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
    Shen, Guoshuang
    Zheng, Fangchao
    Ren, Dengfeng
    Du, Feng
    Dong, Qiuxia
    Wang, Ziyi
    Zhao, Fuxing
    Ahmad, Raees
    Zhao, Jiuda
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [28] Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
    Sikov, William M.
    Berry, Donald A.
    Perou, Charles M.
    Singh, Baljit
    Cirrincione, Constance T.
    Tolaney, Sara M.
    Kuzma, Charles S.
    Pluard, Timothy J.
    Somlo, George
    Port, Elisa R.
    Golshan, Mehra
    Bellon, Jennifer R.
    Collyar, Deborah
    Hahn, Olwen M.
    Carey, Lisa A.
    Hudis, Clifford A.
    Winer, Eric P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (01) : 13 - U34
  • [29] Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
    Strumberg, D
    Richly, H
    Hilger, RA
    Schleucher, N
    Korfee, S
    Tewes, M
    Faghih, M
    Brendel, E
    Voliotis, D
    Haase, CG
    Schwartz, B
    Awada, A
    Voigtmann, R
    Scheulen, ME
    Seeber, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (05) : 965 - 972
  • [30] Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
    Sun, Yongkun
    Niu, Wei
    Du, Feng
    Du, Chunxia
    Li, Shuting
    Wang, Jinwan
    Li, Li
    Wang, Fengqing
    Hao, Yu
    Li, Chuan
    Chi, Yihebali
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9 : 1 - 9
1234